Results 171 to 180 of about 509,115 (292)
Tryptophan metabolite Indole‐3‐aldehyde (I3A) downregulates cytosolic AhR and p‐ERK/c‐MYC proteins, together enhancing STAT3 phosphorylation and tumor immunogenicity. Overexpression of the Trp metabolic enzyme interleukin‐4‐induced gene‐1 (IL4I1) in tumor cells increases intracellular levels of I3A and enhances tumor immunogenicity.
Lei Cui+19 more
wiley +1 more source
Severe Lipoatrophy in a Growth Hormone Deficient Toddler Girl Treated with a Non-Pegylated Long-Acting Growth Hormone. [PDF]
Büyükgebiz A, Demir A.
europepmc +1 more source
Presbycusis: Pathology, Signal Pathways, and Therapeutic Strategy
In ARHL, the stria vascularis, acting as a cochlear battery, gradually loses its ability to maintain the endocochlear potential, leading to impaired hair cell function and progressive hearing loss. Single‐cell sequencing reveals age‐related cellular changes in the cochlea, providing insights into the underlying mechanisms of aging and potential ...
Xiaoxu Zhao+12 more
wiley +1 more source
Cutis Verticis Gyrata: A Secondary Form of a Rare Skin Condition Caused by Growth Hormone Therapy. [PDF]
Foriers B, Demaerel P.
europepmc +1 more source
LRRC8A Regulates Outer Hair Cell Volume and Electromotility and is Required for Hearing
This study identifies LRRC8A‐dependent volume‐regulated anion channels (VRACs) as essential for cochlear outer hair cells' electromotility and auditory signal amplification. LRRC8A deficiency disrupts cell volume control, impairs auditory sensitivity, and causes deafness, while targeted LRRC8A re‐expression restores auditory function.
Shengnan Wang+15 more
wiley +1 more source
Cadaveric Human Growth Hormone-Associated Creutzfeldt-Jakob Disease with Long Latency Period, United States. [PDF]
Ribeiro AS+9 more
europepmc +1 more source
Rational Design of Inner Ear Drug Delivery Systems
Hearing loss is a common disease affecting many people, and inner ear lesions are one of the most important causes. This review focuses on the treatment of inner ear hearing loss by drug delivery systems. It includes the current methods and technologies developed, and it predicts possible directions.
Xiayidan Maimaitikelimu+5 more
wiley +1 more source
GH Therapy in Non-Growth Hormone-Deficient Children. [PDF]
Guzzetti C+3 more
europepmc +1 more source